The therapeutic advantage of alpelisib over fulvestrant in the treatment of patients with HR-positive, HER2-negative breast cancer and other malignancies is further enhanced by a matched/weighted analysis comparing BYLieve with the real-world scenario. Read More ›

In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer. Read More ›

Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events. Read More ›

Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy. Read More ›

Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment. Read More ›

Treatment with ribociclib and an aromatase inhibitor or fulvestrant for hormone receptor–positive, HER2-negative metastatic breast cancer did not increase the risk of thrombosis in the real-world setting. Read More ›

Palbociclib combined with letrozole is associated with improved outcomes for patients with hormone receptor–positive, HER2-negative metastatic breast cancer with lung or liver metastases in the first-line setting Read More ›


During active chemotherapy treatment, adopting an aerobic exercise program may reduce cancer-related fatigue. Read More ›

Patient outcomes could be improved through targeted education for oncology nurses focused on managing treatment-related adverse events. Read More ›

Page 5 of 29


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: